This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Nevro's (NVRO) Q1 Earnings and Sales Beat Estimates, Margins Up
by Zacks Equity Research
Nevro's (NVRO) first-quarter earnings and revenues surpass their respective Zacks Consensus Estimate. The company incurs a loss in the operating level.
Masimo (MASI) Q1 Earnings Beat Estimates, '24 EPS View Up
by Zacks Equity Research
Masimo's (MASI) Q1 healthcare revenues reflect strong sensor orders, which were completely offset by lower capital equipment purchases. Sensor production in Malaysia is likely to improve Healthcare gross margin.
Fresenius Medical (FMS) Q1 Earnings Beat, Operating Margin Up
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.
Barrick (GOLD) Announces Partnership With Geophysx Jamaica
by Zacks Equity Research
The agreement initially grants Barrick (GOLD) access to about 4,000 square kilometers of consolidated land positions across the country.
DOW to Sell Flexible Packaging Laminating Adhesives Business
by Zacks Equity Research
This deal allows DOW to focus even more on core, high-value downstream operations.
Are You Looking for a Top Momentum Pick? Why Ecolab (ECL) is a Great Choice
by Zacks Equity Research
Does Ecolab (ECL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.
Shockwave Medical (SWAV) Q1 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion amid JNJ entering into a definitive agreement to acquire the company.
GE HealthCare (GEHC) Unveils Head-Only MR Scanner SIGNA MAGNUS
by Zacks Equity Research
GE HealthCare's (GEHC) new SIGNA MAGNUS can delve deep into the brain's microstructure, microvasculature and function, providing researchers with a clearer picture of neurological diseases and disorders.
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
Avanos (AVNS) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Avanos' (AVNS) first-quarter results show strong bottom-line improvement along with decent growth in segmental revenues.
Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up
by Zacks Equity Research
Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment
by Zacks Equity Research
GE Healthcare (GEHC) unveils Revolution RT, along with other upgrades, from its portfolio during the ESTRO 2024 Congress.
Here's Why Ecolab (ECL) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DENTSPLY SIRONA (XRAY) Q1 Earnings In Line, Revenues Decline Y/Y
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter 2024 results showcase a decline in year-over-year sales with an improved bottom line.
Cardinal Health (CAH) Beats on Q3 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) third-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.
Baxter (BAX) Q1 Earnings Beat Estimates, '24 EPS View Raised
by Zacks Equity Research
Baxter (BAX) reports better-than-expected first-quarter earnings and sales. BAX's quarterly results reflect solid demand for a range of its medically essential products.
Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Glaukos' (GKOS) first-quarter 2024 results showcase growth in revenues while earnings miss the Zacks consensus Estimate. Loss at the operating level raises concern as well.
Inari Medical (NARI) Q1 Earnings Miss Estimates, OpEx Rises
by Zacks Equity Research
Inari Medical's (NARI) first-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the companies continue to incur operating losses.
Here's Why Ecolab (ECL) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
These 2 Basic Materials Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Here's Why You Should Hold Lantheus (LNTH) in Your Portfolio Now
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
GE HealthCare (GEHC) Q1 Earnings In Line, Sales Volume Decline
by Zacks Equity Research
GE HealthCare's (GEHC) first-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.
Ecolab (ECL) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its first-quarter sales despite business challenges.
Ecolab (ECL) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Ecolab (ECL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.